Kyverna Therapeutics, Inc., a late-stage clinical biopharmaceutical company, reported a net loss of $161.3 million for the year ended December 31, 2025, compared to a net loss of $127.5 million for the previous year. The increased loss was primarily driven by escalating research and development expenses as the company advanced its lead product candidate, miv-cel, through late-stage clinical trials. The company has no products approved for commercial sale and has not generated any revenue from product sales to date. As of December 31, 2025, Kyverna's accumulated deficit stood at $424.8 million.
Research and development expenses for 2025 totaled $133.7 million, a 19% increase from $112.5 million in 2024. This rise was mainly attributed to a $14.2 million increase in external research and development expenses related to miv-cel, reflecting accelerated clinical study activities in KYSA trials for stiff person syndrome (SPS) and generalized myasthenia gravis (gMG), as well as Biologics License Application (BLA) preparation for SPS. General and administrative expenses also increased by 20% to $36.1 million, primarily due to higher personnel-related costs. Interest income decreased by 41% to $9.1 million, due to lower cash, cash equivalents and short-term investment balances.
Key operational developments for Kyverna in 2025 included the completion of a registrational Phase 2 clinical trial for miv-cel in SPS, with plans to submit a BLA in the first half of 2026. The company also initiated a Phase 3 registrational trial for miv-cel in gMG and reported positive interim data from its Phase 2 clinical trial in gMG. In January 2026, the FDA accepted the Investigational New Drug (IND) application for KYV-102, a rapid manufacturing process. As of March 1, 2026, the company had 130 full-time employees, with 94 engaged in research and development activities.
Looking ahead, Kyverna anticipates that its current cash, cash equivalents, and available-for-sale marketable securities, totaling $279.3 million as of December 31, 2025, will be sufficient to fund operations into 2028. These funds are expected to support the SPS BLA filing and commercial launch, as well as the Phase 3 registrational trial in gMG. The company plans to monitor expenses and raise additional capital through equity or debt financings, strategic alliances, and licensing arrangements.
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics is a biopharmaceutical company developing cell therapies, primarily CAR T-cell products, to treat autoimmune diseases. Its lead candidate, KYV-101, targets B-cell-driven conditions like stiff person syndrome, myasthenia gravis, and lupus nephritis, aiming for durable remission through deep B cell depletion. The company leverages proprietary technologies, strategic partnerships, and innovative manufacturing to address unmet medical needs in autoimmune therapeutics.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.